Sandoz Canada launches PrSandoz® Solifenacin on the Canadian market for the treatment of urinary urgency, frequency and incontinence

Sandoz Canada launches PrSandoz® Solifenacin on the Canadian market for the treatment of urinary urgency, frequency and incontinence [1]

Publish Date:

Oct 07, 2015

Boucherville, QC, October 7 – Sandoz Canada announced today the launch of a new drug on the Canadian market, PrSandoz® Solifenacin (solifenacin succinate), which is used in reducing urinary urgency, frequency and incontinence. PrSandoz® Solifenacin is a generic equivalent to the product Vesikur marketed in Canada under the name PrVesicare*. This generic drug is available immediately on the Canadian market.